Fosciclopirox disodium suppresses growth of urothelial cancer by targeting the γ-secretase complex. Fosciclopirox disodium selectively delivers the active metabolite, Ciclopirox , to the entire urinary tract. Ciclopirox has anticancer activity in a number of solid and hematologic malignancies.